Your Body Knows Before You Do: What Wearables, Blood Tests & Genes Can (and Can't) Tell You About Your Allergies

The question you've probably asked your GP — and never quite got a satisfying answer to

Why does pollen season flatten you completely while your partner, sneezing in the same garden, manages fine with a single antihistamine? And why does one June feel unbearable while the next, with seemingly identical pollen counts, barely registers? These aren't rhetorical questions — they're the frontier of allergy science, and researchers are working hard to answer them using three very different lenses: your genes, your blood, and the data streaming from your wrist.

The honest answer right now is that we're getting closer, but we're not there yet. Here's what the evidence actually says — and what it means for you.

---

The science

What your genes can (and can't) tell you

Genetics research into allergic rhinitis has made genuine strides. Scientists have identified multiple variants — clusters of DNA spelling differences called SNPs — that reliably increase the likelihood of developing hayfever in the first place. The most compelling evidence comes from a genome-wide association study (GWAS) involving more than 210,000 individuals, and the SHARE study, which examined 360,000 participants and identified 136 genetic loci shared across allergic conditions including hayfever, eczema, and asthma.

The genes involved read like a who's who of immune regulation. HLA region variants affect how efficiently your immune system presents allergen proteins to T-cells — essentially how loudly it shouts about pollen. Variants in the IL-4, IL-13, and STAT6 pathway (particularly a gene called IL4R) determine how strongly your immune system skews toward the Th2 response that drives allergic inflammation. FOXP3 variants impair the regulatory T-cells that would normally put the brakes on this reaction. TSLP and IL-33 SNPs influence the alarm signals sent by airway lining cells when they detect environmental threats (Bunyavanich et al., 2011; Feng Xiang et al., 2022).

The picture gets more nuanced still: some mutations don't act alone. Loss-of-function variants in the FLG gene — already associated with eczema — appear to work synergistically with IL4R variants, potentially amplifying the allergic cascade beyond what either would produce independently.

But here's the critical limitation, and it's worth being direct about it: virtually all of this research asks the binary question — do you have allergic rhinitis or not? — rather than how bad will your symptoms be? No prospective studies have yet mapped polygenic risk scores against validated symptom severity measures like the Total Nasal Symptom Score (TNSS). Genetics can sketch the outline of your allergy risk; it cannot yet shade in the severity.

What your IgE levels reveal

IgE is the antibody class at the heart of allergic reactions — your immune system's standing army of allergen-recognition molecules. When you encounter grass pollen, allergen-specific IgE on the surface of mast cells triggers their degranulation, flooding your nasal tissue with histamine and other inflammatory mediators that produce the symptoms you know all too well.

So does more IgE mean worse symptoms? Partially. The relationship between total serum IgE and hayfever severity is statistically real but frustratingly modest. Research suggests a 10-fold increase in total IgE is associated with roughly 1.86-fold higher odds of hayfever — meaningful at a population level, but not a reliable individual predictor (Corsico et al., 2017).

Allergen-specific IgE is considerably more informative. Studies show that plant-specific IgE, for instance, carries an odds ratio of around 4.75 for hayfever — nearly three times the predictive power of total IgE. This makes biological sense: specific IgE reflects the actual sensitisation pathway that matters for your symptoms, rather than aggregating responses across every allergen you've ever encountered (Ciprandi et al., 2017).

The complication is the overlap. Many people have meaningfully elevated specific IgE and barely any symptoms during peak season. Others with relatively low IgE levels are incapacitated. This tells us that IgE is part of the severity story — perhaps a necessary condition — but certainly not the whole of it.

What your wearable might one day detect

This is perhaps the most intriguing frontier, and also the most speculative in the context of hayfever specifically.

The underlying logic is compelling: systemic inflammation — regardless of its cause — disrupts autonomic nervous system balance. Proinflammatory cytokines like IL-6 and TNF-α cause vagal withdrawal and sympathetic activation, producing measurable changes in heart rate variability (HRV), resting heart rate, skin temperature, and SpO2. Critically, these physiological shifts can appear days before clinical symptoms emerge.

In conditions like inflammatory bowel disease and rheumatoid arthritis, wearable-derived data have shown genuine predictive power for flares, detectable weeks in advance. In viral respiratory infections, machine learning models applied to continuous wearable data have achieved sensitivity rates as high as 90% for detecting pre-symptomatic immune responses (Siswishanto et al., 2026; Avey et al., 2024). A controlled LPS-challenge study — essentially giving volunteers a standardised inflammatory stimulus — demonstrated that wearable patches could track acute inflammatory biomarker dynamics in real time (Steinhubl et al., 2024).

For hayfever specifically, the picture is more complicated. Allergic rhinitis does appear to alter HRV — but not consistently. Studies in AR patients show that severe allergic states tend to reduce SDNN (a key HRV metric) and shorten RR intervals, suggesting sympathetic dominance. Yet in chronic, lower-grade AR phases, some studies find increased parasympathetic activity compared to non-allergic controls (Kim et al., 2017; Won et al., 2023). The direction of the effect shifts depending on disease phase, severity classification, and measurement methodology.

Daily symptom burden does produce detectable next-day resting heart rate increases — but the effect sizes are small. And crucially, no study has yet validated wearable-based prediction specifically for Th2-mediated allergic inflammation, which operates through different pathways than the innate inflammatory responses that existing wearable research has characterised.

---

What this means for you

If you're a hayfever sufferer who's ever wondered whether a genetic test or a blood IgE result would finally explain why your symptoms are so much worse than average — or why they vary so unpredictably year to year — these findings offer a nuanced answer.

Your genetics do influence your underlying immune wiring, shaping how readily your system tilts toward allergic inflammation and how vigorously it responds to allergen exposure. Your specific IgE levels tell you something real about the depth of your sensitisation. And your heart rate variability almost certainly reflects something about your inflammatory state in real time — we just don't yet have the tools to interpret that signal precisely for hayfever.

The more important practical insight is this: severity is multifactorial in a way that single biomarkers may never fully capture. Pollen load, weather conditions, sleep quality, prior viral infections, stress hormones, and the specific mix of allergens in your local environment all interact with your underlying biology to determine how any given day feels. Personalised hayfever management almost certainly requires integrating multiple data streams — not relying on any single predictor.

---

The evidence landscape — what we know and don't

It's worth being honest about the confidence levels here, because this is an area where enthusiasm can outpace evidence.

Genetics: The association between identified variants and disease risk is well-established across large populations. The evidence for genetic prediction of symptom severity is essentially absent — no prospective studies have paired polygenic risk scores with validated severity measures, and pharmacogenetic data (which genes predict your response to antihistamines or immunotherapy?) barely exist.

IgE: The association between specific IgE and hayfever is moderately well-evidenced, but no systematic review has established reliable sensitivity/specificity thresholds for IgE as a clinical severity predictor. The evidence is conflicting enough that leading allergy guidelines treat it as a diagnostic support tool rather than a severity barometer.

Wearables and HRV: The general principle that wearables can detect systemic inflammation is supported by moderate evidence. The application to allergic rhinitis specifically remains unvalidated. Studies in this area are predominantly small (some as few as 12–72 participants), observational, and heterogeneous in methodology. This is promising territory, not proven territory.

The honest summary: we have meaningful pieces of a personalisation puzzle, but the integrated picture — the one that tells you precisely how bad your season will be and why — remains the work of the coming decade rather than today.

---

What Haelo recommends

Given what the evidence does and doesn't support, here's how to think about personalisation practically:

1. Know your specific allergens, not just your total IgE. If you've had allergy testing, ask for a breakdown of specific IgE results by allergen. Grass pollen IgE, tree pollen IgE, and house dust mite IgE tell you something meaningfully different — and more actionable — than a single total IgE number. If you haven't been tested, it's worth pursuing.

2. Track your symptoms systematically across seasons. The patterns in your own data are currently your most reliable severity predictor. Year-on-year comparisons of symptom timing, peak days, and trigger conditions will reveal patterns that no single biomarker test can replicate.

3. Pay attention to your resting heart rate during peak season. While the evidence isn't yet strong enough to make clinical claims, elevated resting HR during high-pollen days may reflect genuine physiological burden. Think of it as a supportive data point, not a diagnostic tool.

4. Don't overinterpret genetic tests marketed for allergy. Consumer genetic tests can tell you whether you carry variants associated with increased risk of allergic disease — which may be useful context — but they cannot currently tell you how severe your symptoms will be or how you'll respond to treatment. Treat them with appropriate scepticism.

5. Consider the whole picture. Sleep quality, stress load, and concurrent infections meaningfully modulate hayfever severity independently of your underlying biology. The most powerful personalisation strategy right now is monitoring and managing these modifiable factors alongside your allergen exposure.

The science of personal allergy prediction is genuinely advancing. The individual data streams — genetic, immunological, physiological — are each carrying real signal. The work ahead is learning how to read them together.

---